# Cancer in Patients With Gabapentin (GPRD)

> **NCT01236053** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2323608 (actual)

## Conditions studied

- Pain, Neuropathic
- Epilepsy
- Renal Pelvis Cancer
- Pancreatic Cancer
- Breast Cancer
- Nervous System Cancer
- Chronic Pancreatitis
- Stomach Cancer
- Renal Cell Carcinoma
- Diabetes
- Bladder Cancer
- Bone and Joint Cancer
- Penis Cancer
- Anal Cancer
- Cancer
- Renal Cancer

## Interventions

- **DRUG:** Gabapentin prescriptions

## Key facts

- **NCT ID:** NCT01236053
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 2323608 (ACTUAL)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01236053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01236053, "Cancer in Patients With Gabapentin (GPRD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01236053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*